Swiss National Bank Boosts Stake in Novavax, Inc. (NASDAQ:NVAX)

Swiss National Bank raised its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 14.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 283,400 shares of the biopharmaceutical company’s stock after buying an additional 35,600 shares during the quarter. Swiss National Bank owned about 0.18% of Novavax worth $2,279,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in Novavax in the fourth quarter worth $29,000. KBC Group NV increased its holdings in shares of Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. purchased a new stake in shares of Novavax during the 4th quarter valued at about $86,000. AlphaQuest LLC lifted its holdings in shares of Novavax by 290.1% in the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 7,940 shares during the last quarter. Finally, Beirne Wealth Consulting Services LLC grew its position in Novavax by 65.0% in the fourth quarter. Beirne Wealth Consulting Services LLC now owns 16,500 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 6,500 shares in the last quarter. Institutional investors own 53.04% of the company’s stock.

Novavax Price Performance

Shares of NVAX stock opened at $7.26 on Friday. The company has a market capitalization of $1.17 billion, a P/E ratio of -3.21, a P/E/G ratio of 2.85 and a beta of 2.92. The company’s 50-day simple moving average is $8.16 and its two-hundred day simple moving average is $9.41. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) earnings per share. On average, research analysts expect that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NVAX shares. BTIG Research assumed coverage on Novavax in a research note on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective for the company. TD Cowen upgraded shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $18.00.

Insider Activity

In other news, Director James F. Young sold 5,400 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.